Thus, the repurposing potential of TYK2 inhibitors for systemic lupus erythematosus and rheumatoid arthritis identified by genetic evidence in our current study needs clinical validation in an RCT setting. This evidence concerns the gene TYK2 and rheumatoid arthritis.